血管升压药抵抗性低血压、联合血管升压药治疗与血管舒张性休克危重成人的休克表型
这项回顾性队列研究纳入2000年7月至2008年10月匹兹堡大学医学中心8个内外科ICU的5,313例血管舒张性休克危重成人,比较血管升压药抵抗性低血压(VRH,去甲肾上腺素等效剂量>0.2 μg/kg/min持续>6 h)与血管升压药敏感性低血压(VSH,液体复苏后≤0.2 μg/kg/min维持MAP 55–70 mm Hg)的资源利用与1年死亡率。1,291例(24.3%)发生VRH,VRH与急性肾损伤、肾脏替代治疗、ICU住院时间及1年死亡率升高相关,风险校正死亡aOR 2.93(95%CI 2.52–3.40)。与单药治疗相比,联合两种或三种以上血管升压药未降低死亡率。有限混合模型识别出4种患者表型簇,需进一步验证。
要点
- VRH定义为去甲肾上腺素等效剂量>0.2 μg/kg/min持续>6 h,VSH为液体复苏后≤0.2 μg/kg/min维持MAP 55–70 mm Hg。
- 5,313例血管舒张性休克中1,291例(24.3%)发生VRH,VRH组1年死亡率64.7% vs VSH组34.8%(P<0.001)。
- VRH与风险校正死亡 odds 升高相关(aOR 2.93;95%CI 2.52–3.40;P<0.001)。
- 联合两种血管升压药(aOR 0.91;95%CI 0.78–1.06)或三种以上(aOR 0.93;95%CI 0.68–1.27)与单药治疗相比未降低死亡率。
- 有限混合模型识别出4种患者表型簇,在人口学、病情严重度、诊疗过程、血管升压药使用和结局上不同,需进一步验证。
适用人群与场景
- 2000年7月至2008年10月匹兹堡大学医学中心8个内外科ICU收治的血管舒张性休克危重成人。
诊断标准与关键阈值
- 血管升压药抵抗性低血压(VRH):需要去甲肾上腺素等效剂量>0.2 μg/kg/min连续>6 h。
- 血管升压药敏感性低血压(VSH):充分液体复苏后需要≤0.2 μg/kg/min维持MAP在55–70 mm Hg。
研究设计与关键结果
- 回顾性队列研究,纳入5,313例血管舒张性休克患者,其中1,291例(24.3%)发生VRH。
- 与VSH相比,VRH与急性肾损伤发生率升高相关(72.7% vs 65.0%;P<0.001)。
- 与VSH相比,VRH与肾脏替代治疗使用增加相关(26.0% vs 11.0%;P<0.001)。
- VRH组中位ICU住院时间10天(IQR 4.0–20.0)vs VSH组6天(IQR 3.0–13.0),P<0.001。
- VRH组1年死亡率64.7% vs VSH组34.8%(P<0.001)。
- VRH与风险校正死亡 odds 升高相关(aOR 2.93;95%CI 2.52–3.40;P<0.001)。
- 与单药治疗相比,联合两种血管升压药与死亡率无关(aOR 0.91;95%CI 0.78–1.06),联合三种或以上血管升压药与死亡率无关(aOR 0.93;95%CI 0.68–1.27)。
- 有限混合模型识别出4种患者表型簇,在人口学、病情严重度、诊疗过程、血管升压药使用和结局上存在差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在血管舒张性休克成人中,去甲肾上腺素等效剂量>0.2 μg/kg/min持续>6 h的VRH与更高的资源利用和长期死亡风险相关。
- 与单药治疗相比,联合两种或三种以上血管升压药未显示降低死亡风险。
- 作者认为识别出的4种患者表型簇需要进一步验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective: To examine the risk factors, resource utilization, and 1-year mortality associated with vasopressor-resistant hypotension (VRH) compared with vasopressor-sensitive hypotension (VSH) among critically ill adults with vasodilatory shock. We also examined whether combination vasopressor therapy and patient phenotype were associated with mortality. Design: Retrospective cohort study. Setting: Eight medical-surgical intensive care units at the University of Pittsburgh Medical Center, Pittsburgh, PA. Patients : Critically ill patients with vasodilatory shock admitted between July 2000 and October 2008. Interventions : None. Measurements and Main Results: Vasopressor-resistant hypotension was defined as those requiring greater than 0.2 μg/kg per minute of norepinephrine equivalent dose of vasopressor consecutively for more than 6 h, and VSH was defined as patients requiring ≤0.2 μg/kg per minute to maintain MAP between 55 and 70 mm Hg after adequate fluid resuscitation. Of 5,313 patients with vasodilatory shock, 1,291 patients (24.3%) developed VRH. Compared with VSH, VRH was associated with increased risk of acute kidney injury (72.7% vs. 65.0%; P < 0.001), use of kidney replacement therapy (26.0% vs. 11.0%; P < 0.001), longer median (interquartile range [IQR]) intensive care unit length of stay (10 [IQR, 4.0-20.0] vs. 6 [IQR, 3.0-13.0] days; P < 0.001), and increased 1-year mortality (64.7% vs. 34.8%; P < 0.001). Vasopressor-resistant hypotension was associated with increased odds of risk-adjusted mortality (adjusted odds ratio [aOR], 2.93; 95% confidence interval [CI], 2.52-3.40; P < 0.001). When compared with monotherapy, combination vasopressor therapy with two (aOR, 0.91; 95% CI, 0.78-1.06) and three or more vasopressors was not associated with lower mortality (aOR, 0.93; 95% CI, 0.68-1.27). Using a finite mixture model, we identified four unique phenotypes of patient clusters that differed with respect to demographics, severity of illness, processes of care, vasopressor use, and outcomes. Conclusions: Among critically ill patients with vasodilatory shock, VRH compared with VSH is associated with increased resource utilization and long-term risk of death. However, combination vasopressor therapy was not associated with lower risk of death. We identified four unique phenotypes of patient clusters that require further validation.
参考来源
- Priyanka P, Chang CH, Chawla LS, et al. VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK. Shock. 2022. PMID: 36018286. doi:10.1097/SHK.0000000000001980
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。